SCHEMBL842096

SCHEMBL842096

NCC1(O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3198564 0.97
Hydrochloric Acid SCHEMBL31329179 0.97
SCHEMBL944236 0.93
SCHEMBL491716 0.90 TSHR (0.41)
SCHEMBL17288070 0.90 TSHR (0.41)
SCHEMBL30087352 0.90 TSHR (0.41)
Hydrochloric Acid SCHEMBL3198552 0.90
SCHEMBL3043105 0.90 TSHR (0.41)
SCHEMBL56742 0.90
Hydrochloric Acid SCHEMBL491971 0.88 USP2 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106061967-A Heteroaryl substituted nicotinamide compounds 百时美施贵宝公司 2016-10-26 CN claimed
US-20260098036-A1 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2026-04-09 US disclosed
US-20260085070-A1 HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
EP-4705275-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2026-03-11 EP disclosed
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 US disclosed
US-12522594-B2 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2026-01-13 US disclosed
US-20250388568-A1 NLRP3 INHIBITORS KODIAK SCIENCES INC (US) 2025-12-25 US disclosed
EP-4642772-A1 NLRP3 INFLAMMASOME INHIBITORS Astrazeneca AB (SE) 2025-11-05 EP disclosed
US-20250332138-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER VIVOZON, INC. (KR) 2025-10-30 US disclosed
US-20250326770-A1 BENZOTRIAZOLE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-10-23 US disclosed
US-20070155767-A1 Sulfone substituted imidazo ring ethers 3M INNOVATIVE PROPERTIES COMPANY 2007-07-05 US disclosed
EP-1784180-A2 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-16 EP disclosed
EP-1765348-A2 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company (US) 2007-03-28 EP disclosed
CN-1914203-A Sulfone substituted imidazo ring ethers 3M INNOVATIVE PROPERTIES CO (US) 2007-02-14 CN disclosed
WO-2006100208-A1 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES N.V. ORGANON (NL) 2006-09-28 WO disclosed
EP-1694674-A2 SULFONE SUBSTITUTED IMIDAZO RING ETHERS 3M Innovative Properties Company (US) 2006-08-30 EP disclosed
WO-2006029115-A2 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 WO disclosed
WO-2006028545-A2 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 WO disclosed
WO-2005123079-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-12-29 WO disclosed
WO-2005076783-A2 SULFONE SUBSTITUTED IMIDAZO RING ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-08-25 WO disclosed